Develops drugs for HIV, hepatitis, and cancer.
Jun 2026Revenue $30.5B/yrExpenses $33.0B/yr
Fell below break-even Jun 2026
Figures by year
When will Gilead Sciences be profitable again?
Its expenses passed its revenue in Jun 2026. In the 12 months to Jun 2026, revenue was $30.5B and expenses $33.0B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $29.4B | $19.4B | $10.0B |
| Dec 2024 | $28.8B | $27.1B | $1.66B |
| Dec 2023 | $27.1B | $19.5B | $7.61B |
| Dec 2022 | $27.3B | $20.0B | $7.33B |
| Dec 2021 | $27.3B | $17.4B | $9.92B |
| Dec 2020 | $24.7B | $20.6B | $4.07B |
| Dec 2019 | $22.4B | $18.2B | $4.29B |
| Dec 2018 | $22.1B | $13.9B | $8.20B |
| Dec 2017 | $26.1B | $12.0B | $14.1B |
| Dec 2016 | $30.4B | $12.8B | $17.6B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.